Evidence map›Paper›PMID 27317792›Full record

Trial reportBlood2016

Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism.

Lindsey Hawke, Mackenzie L Bowman, Man-Chiu Poon, Mary-Frances Scully, Georges-Etienne Rivard, Paula D James

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Lindsey HawkeDepartment of Pathology and Molecular Medicine and.
Mackenzie L BowmanDepartment of Medicine, Queen's University, Kingston, ON, Canada;
Man-Chiu PoonDepartment of Medicine, Foothills Medical Centre, Alberta Health Services, University of Calgary, Calgary, AB, Canada;
Mary-Frances ScullyDivision of Hematology/Oncology, Health Sciences Centre, St. Johns, NL, Canada; and.
Georges-Etienne RivardClinique d'Hematologie, Centre Hospitalier Universitaire St. Justine, Montréal, QC, Canada.
Paula D JamesDepartment of Medicine, Queen's University, Kingston, ON, Canada;
Queen's University · CACentre Hospitalier Universitaire Sainte-Justine · CAFoothills Medical Centre · CAHealth Sciences Centre · CA

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
NHLBI NIH HHS P01 HL081588
6 · The paper itself

Abstract

Approximately 10% of von Willebrand factor (VWF) gene mutations are thought to alter messenger RNA (mRNA) splicing through disruption of consensus splice sites. This mechanism is likely underrecognized and affected by mutations outside consensus splice sites. During VWF synthesis, splicing abnormalities lead to qualitative defects or quantitative deficiencies in VWF. This study investigated the pathologic mechanism acting in 3 von Willebrand disease (VWD) families with putative splicing mutations using patient-derived blood outgrowth endothelial cells (BOECs) and a heterologous human embryonic kidney (HEK 293(T)) cell model. The exonic mutation c.3538G>A causes 3 in-frame splicing variants (23del, 26del, and 23/26del) which cannot bind platelets, blood coagulation factor VIII, or collagen, causing VWD through dominant-negative intracellular retention of coexpressed wild-type (WT) VWF, and increased trafficking to lysosomes. Individuals heterozygous for the c.5842+1G>C mutation produce exon 33 skipping, exons 33-34 skipping, and WT VWF transcripts. Pathogenic intracellular retention of VWF lacking exons 33-34 causes their VWD. The branch site mutation c.6599-20A>T causes type 1 VWD through mRNA degradation of exon 38 skipping transcripts. Splicing ratios of aberrant transcripts and coexpressed WT were altered in the BOECs with exposure to shear stress. This study provides evidence of mutations outside consensus splice sites disrupting splicing and introduces the concept that VWF splicing is affected by shear stress on endothelial cells.

Indexed as

Point MutationRNA Splice SitesRNA SplicingExonsFemaleHEK293 CellsHumansMaleRNA, MessengerRNA Stabilityvon Willebrand Disease, Type 1von Willebrand Disease, Type 3von Willebrand FactorRNA, MessengerRNA Splice Sitesvon Willebrand Factor

Identifiers

PMID27317792
PMCPMC4965908
OpenAlexW2424323355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.